1. OKYO Pharma rang the Nasdaq Opening Bell, showcasing its innovations. 2. Urcosimod shows positive Phase 2 results for neuropathic corneal pain. 3. No FDA-approved therapies exist for neuropathic corneal pain currently. 4. OKYO plans a larger trial for urcosimod starting in Q1 2026. 5. Cerrone emphasized commitment to improve patient outcomes with groundbreaking therapies.
FAQ
Why Bullish?
The ringing of the Nasdaq Opening Bell highlights investor interest and showcases progress. Historical examples like Moderna's significant increase post-Nasdaq events illustrate potential for OKYO's stock appreciation.
How important is it?
The article highlights significant milestones for OKYO, increasing market visibility and investor confidence. Positive Phase 2 results further secure its strategic position in a rapidly developing market.
Why Short Term?
Immediate positivity from the Nasdaq ceremony may boost investor sentiment quickly. However, longer-term impacts depend on clinical trial outcomes.
OKYO Pharma Rings Opening Bell at Nasdaq to Celebrate Advances in Neuropathic Corneal Pain Treatment
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company, is making headlines today as its Executive Chairman and Founder, Gabriele Cerrone, along with the management team, rings the Opening Bell at the Nasdaq MarketSite in Times Square, New York. This ceremony, scheduled from 9:15 AM to 9:45 AM ET, marks a significant milestone for OKYO, underlining their commitment to developing innovative treatments for neuropathic corneal pain (NCP).
Celebrating Clinical Advancements with Urcosimod
The event celebrates OKYO's continued progress, particularly highlighting the ongoing clinical development of its lead candidate, urcosimod. This groundbreaking therapy, a lipid-conjugated chemerin peptide agonist, specifically targets the ChemR23 G-protein-coupled receptor. Currently, there are no FDA-approved therapies for NCP, making this development especially crucial for patients suffering from this painful condition.
"This is a proud moment for OKYO Pharma and a testament to the hard work and dedication of our exceptional team who are working to improve patient outcomes," stated Gabriele Cerrone. "Ringing the Nasdaq Opening Bell is a powerful celebration of our unwavering commitment to transforming patient outcomes through groundbreaking therapies for ocular pain."
Recent Clinical Successes and Future Plans
OKYO Pharma is witnessing positive momentum, recent results from Phase 2 trials for urcosimod have demonstrated favorable outcomes in both corneal nerve health and pain reduction among patients with NCP. This strengthens the company’s position as a leader in the development of effective treatments for a condition that currently lacks approved options.
The live broadcast of the Opening Bell ceremony can be viewed at 9:30 AM ET on Nasdaq’s official channels. To access the stream, please visit: Nasdaq Bell Ringing Ceremony.
Understanding Neuropathic Corneal Pain (NCP)
Neuropathic corneal pain is characterized by severe discomfort and sensitivity affecting the eyes, face, or head. Although the exact cause remains unclear, it is often linked to nerve damage to the cornea and inflammation. Currently, treatments available are mostly off-label, and there is an urgent need for FDA-approved therapies to alleviate this debilitating condition.
About Urcosimod and OKYO Pharma
Urcosimod, previously known as OK-101, is a promising candidate that has shown potential in alleviating both inflammation and pain caused by NCP. It has already demonstrated statistical significance across multiple endpoints in earlier clinical trials, including a notable study involving 240 patients for dry eye disease.
OKYO Pharma Limited (NASDAQ: OKYO) is focused on deploying cutting-edge therapies to address unmet medical needs in ocular health, particularly in neuropathic corneal pain. Following the success of its recent Phase 2 trial, OKYO plans to initiate a larger multicenter trial for urcosimod in Q1 2026.
For more information about OKYO Pharma and their commitment to innovative treatments, visit: www.okyopharma.com.
Contact Information
- Gary S. Jacob, Chief Executive Officer
+44 (0)20 7495 2379 - Business Development & Investor Relations
Paul Spencer
+44 (0)20 7495 2379